XprESS Maxillary Balloon Dilation Study
XprESS Maxillary Sinus Balloon Dilation Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Minnesota
-
Plymouth, Minnesota, United States, 55447
- Entellus Medical
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Synergy ENT Specialists
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Be at least 18 years of age.
- Must have uncomplicated sinusitis of the maxillary sinuses with or without anterior ethmoid disease.
- Meet EITHER the Anthem Coverage Guideline OR BlueCross BlueShield of North Carolina Corporate Medical Policy for medically necessary functional endoscopic sinus surgery (FESS) to treat uncomplicated sinusitis.
- Have a CT scan within 6 months prior to enrollment.
- Be mentally and physically capable (as per physician discretion) to participate in the investigation.
- Be willing and able to sign the study-specific informed consent prior to any study-related procedures.
- Be willing and able to undergo balloon dilation in the clinic setting.
Exclusion Criteria:
- Have evidence of posterior ethmoid, sphenoid or frontal sinus (excludes presence of mucous retention cysts) disease requiring endoscopic sinus surgery or balloon dilatation.
- Have presence of features consistent with sinus fungal disease.
- Have evidence of gross polypoid disease within any of the sinuses or within the infundibulum.
- Require concurrent nasal surgery (eg, septoplasty, turbinate reduction, etc).
- Have previous sinus surgery (eg, sinus surgery or balloon sinuplasty).
- Have nasal surgery (eg, septoplasty, turbinate reduction) performed within 3 months prior to enrollment.
- Have any anatomical anomaly (ie, severe septal deviation) preventing transnasal access to the maxillary sinus outflow tract.
- Have a history of primary ciliary dysfunction.
- Have hemophilia.
- Be currently undergoing, or have undergone in the past 6 months, chemotherapy for cancer or radiation therapy in the head or neck region.
- Have a history of cystic fibrosis.
- Have Sampter's Triad (ie, defined as having all 3 of the following: aspirin sensitivity, asthma, and sinonasal polyposis).
- Have known sinonasal tumors or obstructive lesions.
- Be pregnant at the time of enrollment.
- Be unable to stop anticoagulant medication (eg, warfarin) until the International Normalized Ratio (INR) is below 1.5.
- Be unable to stop antiplatelet (eg, clopidogrel, aspirin, etc.) for at least 7 days prior to study procedure.
- Be currently participating in any other drug or device clinical studies excluding postapproval or marketing registry studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Balloon sinus dilation
Balloon dilation of the maxillary sinus using a transnasal approach.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
SNOT-20 Score
Time Frame: Baseline and 6 months post procedure
|
The 20-item Sino-Nasal Outcomes Test (SNOT-20) is a validated patient-reported outcome measure for assessing the presence and severity of symptoms of chronic rhinosinusitis.
Symptoms on the SNOT-20 survey are each rated on a scale from 0 (no problem) to 5 (problem as bad as it can be) and the 20 symptom scores are averaged to provide a total score ranging from 0 to 5. The minimal clinically important difference in the SNOT-20 has been determined to be a reduction greater or equal to 0.8 in the total SNOT-20 score.
|
Baseline and 6 months post procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recovery Time
Time Frame: 1 week post procedure
|
Patient-reported time from procedure to ability to return to normal daily activities.
|
1 week post procedure
|
|
Procedural Pain Scores
Time Frame: Immediately post procedure
|
Procedure pain/discomfort on a scale of 0 (no pain) to 10 (severe pain) as reported by the participant.
|
Immediately post procedure
|
|
Revision Rate
Time Frame: 6 Months post procedure
|
The number of participants who require revision sinus surgery during the study duration.
|
6 Months post procedure
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: James D. Gould, MD, Synergy ENT Specialists
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2091-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Sinusitis
-
NCT05095961WithdrawnChronic Sinus Disease | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Maxillary Bilateral | Chronic Sinusitis - Frontoethmoidal
-
NCT03472144UnknownChronic Sinusitis | Nasal Polyps | Chronic Sinusitis, Ethmoidal | Chronic Sinusitis, Sphenoidal | Chronic Sinusitis - Frontoethmoidal | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinusitis - Ethmoidal Anterior | Nasal Polyp - Posterior
-
NCT07174115RecruitingChronic Sinusitis Without Nasal Polyps
-
NCT07560254CompletedSinusitis | Rhinosinusitis | Chronic Rhino-sinusitis
-
NCT03519061WithdrawnChronic Sinusitis | Chronic Sinus Infection | Chronic Sinusitis - Ethmoidal, Posterior | Chronic Sinus Congestion
-
NCT04645511RecruitingMaxillary Sinusitis | Eustachian Tube Dysfunction | Sinusitis, Chronic | Sinusitis Recurrent
-
NCT05295459CompletedChronic Sinusitis | Chronic Rhinosinusitis (Diagnosis)
-
NCT05863468Not yet recruitingChronic Sinusitis, Ethmoidal
-
NCT02668302CompletedChronic Sinusitis, Ethmoidal
-
NCT01623323Completed
Clinical Trials on Balloon sinus dilation
-
NCT01525849Completed
-
NCT03390257Completed
-
NCT01685229Completed
-
NCT01714687Completed
-
NCT07349654RecruitingLiver Cirrhosis | Ascites Hepatic | Variceal Bleeding, Cirrhosis | Hepatic Encephalopathy (HE)
-
NCT04858802CompletedChronic Rhinosinusitis (Diagnosis)
-
NCT03521843UnknownPeripheral Artery Disease | In-stent Restenosis
-
NCT05107024Not yet recruitingde Novo Coronary Lesions